Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI
Information source: New York University School of Medicine
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Myocardial Infarcton
Intervention: fibrinolytic therapy or combination reduced fibrinolytic therapy (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: New York University School of Medicine Official(s) and/or principal investigator(s):
Harmony Reynolds, Principal Investigator, Affiliation: NYU School of Medicine
Summary
This study evaluated differences between men and women in the presentation, management and
outcome of heart attacks within the GUSTO V study.
Clinical Details
Official title: Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI; Results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries - V Trial
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Detailed description:
The Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO) V
trial examined a large, contemporary cohort of women and men with ST elevation myocardial
infarction (STEMI) treated with fibrinolytic therapy. The objective of the present study was
to evaluate sex differences in presentation, management and outcome in GUSTO V.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- inclusion into GUSTO V
Exclusion Criteria:
- lack of availability of data (database study)
Locations and Contacts
NYU School of Medicine, New York, New York 10016, United States
Additional Information
Related publications: Topol EJ; GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001 Jun 16;357(9272):1905-14. Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowski Z, Betriu A, Booth JE, Wolski K, Waller M, Topol EJ; Global Use of Strategies To Open Coronary Arteries Investigators (GUSTO). Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA. 2002 Nov 6;288(17):2130-5.
Last updated: October 27, 2005
|
